STAT3 and hyperuricemia: In addition, in vitro, the JAK inhibitor ruxolitinib can alleviate hyperuricemia-induced mitochondrial dysfunction and oxidative stress by affecting the JAK2/STAT3/HMGCS2 signaling pathway.